Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation

Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation

Background: Real-world evidence on direct oral anticoagulant outcomes among Non-Valvular Atrial Fibrillation (NVAF) patients is limited. We aimed to evaluate stroke/systemic embolism (SE) and major bleeding (MB) risks among NVAF patients continuing or switching to different oral anticoagulants. Meth...

Full description

Bibliographic Details
Main Authors: Steven Deitelzweig, Amiee Kang, Jenny Jiang, Chuan Gao, Xuemei Luo, Nipun Atreja, Stella Han, Dong Cheng, Saarusri R Loganathan, Gregory Y. H. Lip
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Journal of Clinical Medicine
Subjects:
direct oral anticoagulants
non-valvular atrial fibrillation
real world
stroke
major bleeding
switching
Online Access:https://www.mdpi.com/2077-0383/13/4/1073

Internet

https://www.mdpi.com/2077-0383/13/4/1073

Similar Items